Q1 2013 filing for BioMarin's enzyme replacement therapy
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical plans to file for approval early next year of its enzyme replacement therapy GALNS (N-acetylgalactosamine-6 sulphatase also known as BMN-110), for the treatment of patients with the rare lysosomal storage disorder mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.